Prostate Cancer
Prostate cancer patients were treated by sabarubicin
Published in Vaccine Weekly, April 5th, 2006
According to recent research published in the European Journal of Cancer, "Sabarubicin, a new synthetic anthracycline analogue, was evaluated for safety and efficacy in a multicentre phase II study in patients with advanced hormone refractory prostate cancer (HRPC). Thirty seven patients were included, of which 34 were evaluable for PSA response according to Bubley's criteria."
"Sabarubicin was administered as a short (30 min) intravenous infusion at a dose of 80 Mg/m2 every 3 weeks," explained W. Fiedler and colleagues, University of Hamburg. "The main toxicity...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-04-05)
More Articles from Vaccine Weekly
- HIV/AIDS Vaccine
HIV vaccine trial participation barriers among disadvantaged minorities determined - Influenza Vaccines
Influenza virus study demonstrates uneven distribution of MHC class II epitopes - SARS Vaccines
SARS coronavirus vaccine has been developed - Smallpox Vaccines
Vaccinia and smallpox viruses were neutralized by monoclonal antibodies - Vaccine Safety
Sudden infant death syndrome case is linked to hexavalent vaccine - Adenovirus Vaccine
Vaccines elicit CD8+T cell immunity under extreme leukopenia - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
